SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SAN DIEGO, Nov. 03, 2016 -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics, today announced that three abstracts detailing preclinical data on P-BCMA-101, the company’s BCMA-specific CAR-T drug candidate, have been selected for presentation at the American Society of Hematology (ASH) Annual Meeting. The studies explore utility and performance of Poseida’s proprietary CAR-T modifications using its piggyBac™ non-viral gene delivery system and Centyrin binding scaffold. Data will be presented at the 2016 ASH Annual Meeting in San Diego on December 3rd and 5th. Abstracts are currently available online at http://www.hematology.org/Annual-Meeting/.
The following abstracts will be presented:
Presentation Title: A Novel BCMA-Specific, Centyrin-Based CAR-T Product for the Treatment of Multiple Myeloma
Abstract Number: 2127
Date and Time: 5:30 p.m. - 7:30 p.m., Saturday, December 3, 2016
Location: San Diego Convention Center, Hall GH
Presentation Title: piggyBac™-Produced CAR-T Cells Exhibit Stem-Cell Memory Phenotype
Abstract Number: 2167
Date and Time: 5:30 p.m. - 7:30 p.m., Saturday, December 3, 2016
Location: San Diego Convention Center, Hall GH
Presentation Title: Development of Novel Non-Immunoglobulin Centyrin-Based CARs (CARTyrins) Targeting Human BCMA
Abstract Number: 4557
Date and Time: 6:00 p.m. - 8:00 p.m., Monday, December 5, 2016
Location: San Diego Convention Center, Hall GH
About Poseida Therapeutics, Inc.
Poseida Therapeutics is translating best-in-class gene editing technologies into lifesaving treatments. The company is developing CAR T-cell immunotherapies for multiple myeloma and other cancer types, as well as gene therapies for orphan diseases. Poseida is also partnered with Janssen Biotech to develop allogeneic CAR T-cell therapies using Poseida’s gene editing platform. Poseida has assembled a suite of industry-leading gene editing technologies, including the piggyBac™ DNA Modification System, XTN™ TALEN and NextGEN™ CRISPR site-specific nucleases, and Footprint-Free™ Gene Editing (FFGE). For more information, visit www.poseida.com.
Corporate Communications Contact: Jason Spark Canale Communications 619-849-6005 [email protected]
